Skip to content

Precision Allosteric Discovery at Scale

Expanding the druggable landscape powered by the AllotarX™ engine

Physics-drivenAI-guidedLab-in-the-loop
SCROLL
Our mission

To turn protein dynamics into selective, validated therapeutic opportunities: uncovering actionable regulatory mechanisms and designing interventions for precise functional control.

Protein motion

Proteins are machines in motion.


A static structure captures only one state. AllotarX™ samples the conformational ensemble directly, revealing the dynamic states that shape protein function. It does this with over 1000× less compute than established enhanced-sampling workflows such as replica-exchange umbrella sampling applied to the same protein.

Regulatory sites and mechanism

As the protein moves, hidden regulatory sites emerge.


AllotarX™ identifies allosteric sites with ~90% benchmarked accuracy. Interpretable AI ranks allosteric sites, including transient pockets revealed by protein motion, by druggability, dynamics and selectivity signatures.

Selectivity first

Target the right site. Design for precision.


We design site-specific modalities (small molecules, macrocyclic peptides and designed scaffolds) with selectivity considered from site prioritization through molecular design, binding and functional evaluation.

Closed loop

Every round, more selective.


Each design round is tested against the target and off-targets to assess selectivity. Every result, hit or miss, shapes the next round, driving progressively greater target selectivity.

Impact

Mechanism-driven precision to drug discovery

Faster tractability
Undruggable → druggable

Transform undruggable and novel targets into tractable opportunities through dynamics- and mechanism-driven allosteric targeting.

Selectivity-first
Safer by design

Minimize off-target risk from the earliest stages of discovery using AI-guided selectivity signatures.

Precision
Function-level control

Deliver higher-quality candidates that enable precise control of protein function and signaling through selective allosteric modulation.

Accelerated discovery
Shorter cycles

Accelerate design cycles through ultra-fast sampling and closed-loop learning.

Our approach

Three ideas behind every Allotar program

SARS-CoV-2 spike trimer. The open-closed transition, generated on one NVIDIA RTX 2080 Ti in 2 hours 16 minutes.
Physics-driven

Physics-based hybrid simulation across nanosecond to millisecond timescales maps how each target protein moves.

AI-guided

Interpretable AI finds allosteric sites and selectivity signatures across the whole conformational landscape.

Lab-in-the-loop

Functional validation with partner laboratories feeds every result, hit or miss, back into the next design cycle.

Insights

News & Updates

Allotar awarded $504K NIH SBIR Phase I grant to advance selective Alzheimer’s therapeutics

The National Institute on Aging backs Allotar’s AllotarX™-driven program to discover selective allosteric modulators for Alzheimer’s disease.

Show more

Research reported here is supported by the National Institute on Aging of the National Institutes of Health under Award Number R43AG102306. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Allotar Therapeutics launches to unlock allosteric medicines

A new company turning protein dynamics into selective, validated therapeutics.

Ready to unlock novel targets?